CureMatch

05/10/2026

🌸 Happy Mother’s Day 🌸
Today, we honor the incredible mothers, grandmothers, daughters, sisters, and mother figures who fill our lives with strength, love, and resilience.
At , we are committed to supporting women and their families through precision oncology. Because every mother deserves the best possible chance at a long, healthy future — armed with personalized insights and advanced treatment options tailored to her unique cancer profile.
To all the mothers navigating or surviving cancer: your courage inspires us daily. To every woman prioritizing her health and her family’s well-being: thank you for leading by example.
Wishing you a beautiful day filled with love, joy, and well-deserved celebration. 💐
Let’s continue advancing women’s cancer early detection and precision care together.

02/05/2026

At CureMatch, we see cancer not just as a diagnosis, but as a deeply personal story—one unique molecular fingerprint at a time.

Every day, we receive messages that stay with us:

A daughter writing on behalf of her father, asking if there’s still a path forward when standard options have run out.

A young mother fighting stage IV, determined to walk her child down the aisle someday.

An oncologist who refuses to accept “there’s nothing more we can do,” reaching out in the quiet hours for one more combination that might change everything.

Behind each of those messages is real courage—and real lives hanging in the balance.

Our system serves as a GPS that helps navigate cancer complexity. It is an “Assistive AI” physicians use to inform their therapy decisions on molecular personalized basis.

Our platform doesn’t promise miracles. What it does is give precision where there was once guesswork: analyzing a patient’s full tumor profile, filtering, scoring, and ranking most molecularly matching therapies (including combinations), incorporating all the latest scientific evidence, FDA labels, drug mechanisms, resistance and sensitivity markers, and clinical trials into its algorithms and generating a concise report.

We’ve seen progression-free survival improve significantly in patients treated with high-match combinations.

We’ve watched physicians gain clarity in minutes instead of days or weeks. And most importantly, we’ve witnessed hope rekindled—not as false optimism, but as actionable, science-backed possibility.

Cancer may feel relentless, but it is not unbeatable.

Every mutation tells a story.

Every story deserves the best chapter possible.

If you’re an oncologist, a researcher, a patient advocate, or someone who’s been touched by cancer—thank you for fighting alongside us.

If you’re facing this disease or supporting someone who is—know that precision medicine is evolving faster than ever, and we’re here to help light the way.

Let’s keep turning data into decisions, despair into determination, and “what if” into “what now.”

Together, we outsmart cancer—one patient at a time. Razelle Kurzrock

01/06/2026

10/22/2025

We are at in talking about

There are hundreds of cancer drugs representing millions of combinations, each cancer has 5 mutations on average, meaning over a trillion patterns. This is beyond human cognition. Our KRR steps in on clinical decision support, as well as patient matching for trials.

08/21/2025

CureMatch considers all possible novel 2- and 3- drug combinations as well as known ones of the 300 or so cancer drugs, as this means millions of possibilities (>4.5M), and with 5+ markers per molecular profile of each cancer, there are TRILLIONS of possible patterns. To generate and then narrow down to only top most fitting options…navigating this complexity is the problem we solve.

05/23/2025

Our ASCO paper is now published! This was in collaboration with one of the largest Clincial Research Organizations, , TransThera, MD Anderson & Wisconsin College of Medicine.

The unique scoring approach is first of its kind, and this work marks a huge advance in precision oncology taking molecular matching to the next level of validity.

https://www.linkedin.com/posts/curematch_use-of-an-in-silico-clinical-trial-intelligence-activity-7331462868925677568-psPN?utm_medium=ios_app&rcm=ACoAAAFUWAEBt6BacDgB377mB-ABD_NvDLokZOo&utm_source=social_share_send&utm_campaign=gmail

CureMatch results predicting clinical trial outcomes now published and live on the ASCO website:

https://lnkd.in/dpTSEvBs

We are proud to have delivered valuable insights in collaboration with TransThera Biosciences, Inc. on their Phase II clinical trial data of tinengotinib - a multikinase inhibitor targeting specific FGF family receptors.

CureMatch scores for 37 cholangiocarcinoma patients were produced using genomic profiling data (next-gen sequencing, ), as well as the drug targeting profile as inputs. Score thresholds were also determined.

In these molecular analyses CureMatch was BLINDED as to clinical outcomes.

When the outcomes were revealed, our score was predictive with incredible accuracy (p

This link will take you to a page that’s not on LinkedIn

03/09/2025

02/18/2025

A great quote from our co-founder Dr. Razelle Kurzrock highlighting the CureMatch value add:

“The average tumor has 5 genomic alterations, and if there are about 700 cancer genes, that means greater than one trillion patterns.“

01/30/2025

Webinar moderated by Director at The Sheba Medical Center at Tel Hashomer on CureMatch. Our Co-founder Dr. Razelle Kurzrock discussed how we assist in personalized treatment, match molecular markers to enable tailored combos to address as many biomarkers as possible w/each patient’s cancer:

This link will take you to a page that’s not on LinkedIn

01/23/2025

What we shared on the The White House post on this topic:

We are excited as to the attention being given to the convergence of & the fight against . At CureMatch we are doing this already with EXISTING drugs available & helping get patients matched to trials to accelerate the process of clearance.

We are like a guidance system. CureMatch does not do the NGS lab work (just like GPS tools do not build roads).

However we address the cancer complexity problem. The average tumor has 5 genomic alterations. If there are about 700 cancer genes, that means greater than one trillion patterns. Moreover, if there are about 300 drugs in oncology, there are approximately 45,000 two-drug combinations and about 4.5 million three-drug combinations. These numbers illustrate the need of a "GPS" guidance system since this is beyond human cognition. That is what we do with NGS from any lab, plus transcriptomics, protein alterations etc.